There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Crispr Therapeutics AG (CRSP) with bullish sentiments.
Vertex Pharmaceuticals (VRTX)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $220.00. The company’s shares closed last Monday at $213.87, close to its 52-week high of $214.20.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.2% and a 46.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vertex Pharmaceuticals with a $228.60 average price target, which is a 7.3% upside from current levels. In a report issued on November 12, SunTrust Robinson also initiated coverage with a Buy rating on the stock with a $235.00 price target.
See today’s analyst top recommended stocks >>
Crispr Therapeutics AG (CRSP)
In a report released today, Alan Carr from Needham maintained a Buy rating on Crispr Therapeutics AG, with a price target of $84.00. The company’s shares closed last Monday at $69.06, close to its 52-week high of $74.00.
According to TipRanks.com, Carr is a 1-star analyst with an average return of -0.7% and a 41.9% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Lexicon Pharmaceuticals, and Phathom Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $65.58 average price target, which is a 5.8% upside from current levels. In a report issued on November 12, Oppenheimer also upgraded the stock to Buy with a $65.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
